Tags

Type your tag names separated by a space and hit enter

Randomized controlled trial of fish oil supplementation in pregnancy on childhood allergies.

Abstract

BACKGROUND

Diets high in n-3 long chain polyunsaturated fatty acids (LCPUFA) may modulate the development of IgE-mediated allergic disease and have been proposed as a possible allergy prevention strategy. The aim of this study was to determine whether n-3 LCPUFA supplementation of pregnant women reduces IgE-mediated allergic disease in their children.

METHODS

Follow-up of children (n = 706) at hereditary risk of allergic disease in the Docosahexaenoic Acid to Optimise Mother Infant Outcome randomized controlled trial. The intervention group (n = 368) was randomly allocated to receive fish oil capsules (providing 900 mg of n-3 LCPUFA daily) from 21 weeks' gestation until birth; the control group (n = 338) received matched vegetable oil capsules without n-3 LCPUFA. The diagnosis of allergic disease was made during medical assessments at 1 and 3 years of age.

RESULTS

No differences were seen in the overall percentage of children with IgE-mediated allergic disease in the first 3 years of life between the n-3 LCPUFA and control groups (64/368 (17.3%) vs 76/338 (22.6%); adjusted relative risk 0.78; 95% CI 0.58-1.06; P = 0.11). Eczema was the most common allergic disease; 13.8% of children in the n-3 LCPUFA group had eczema with sensitization compared with 19.0% in the control group (adjusted relative risk 0.75; 95% CI 0.53-1.05; P = 0.10).

CONCLUSIONS

Overall, n-3 LCPUFA supplementation during pregnancy did not significantly reduce IgE-associated allergic disease in the first 3 years of life. Further studies should examine whether the nonsignificant reductions in IgE-associated allergies are of clinical and public health significance.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Women's & Children's Health Research Institute, North Adelaide, SA, Australia; School of Paediatrics and Child Health, University of Western Australia, Subiaco, WA, Australia.

    , , , , ,

    Source

    Allergy 68:11 2013 Nov pg 1370-6

    MeSH

    Allergens
    Animals
    Asthma
    Child, Preschool
    Dietary Supplements
    Early Diagnosis
    Eczema
    Fatty Acids, Omega-3
    Female
    Fish Oils
    Food Hypersensitivity
    Humans
    Hypersensitivity
    Infant
    Male
    Pregnancy
    Rhinitis, Allergic
    Rhinitis, Allergic, Perennial

    Pub Type(s)

    Journal Article
    Multicenter Study
    Randomized Controlled Trial
    Research Support, Non-U.S. Gov't

    Language

    eng

    PubMed ID

    24111502

    Citation

    Palmer, D J., et al. "Randomized Controlled Trial of Fish Oil Supplementation in Pregnancy On Childhood Allergies." Allergy, vol. 68, no. 11, 2013, pp. 1370-6.
    Palmer DJ, Sullivan T, Gold MS, et al. Randomized controlled trial of fish oil supplementation in pregnancy on childhood allergies. Allergy. 2013;68(11):1370-6.
    Palmer, D. J., Sullivan, T., Gold, M. S., Prescott, S. L., Heddle, R., Gibson, R. A., & Makrides, M. (2013). Randomized controlled trial of fish oil supplementation in pregnancy on childhood allergies. Allergy, 68(11), pp. 1370-6. doi:10.1111/all.12233.
    Palmer DJ, et al. Randomized Controlled Trial of Fish Oil Supplementation in Pregnancy On Childhood Allergies. Allergy. 2013;68(11):1370-6. PubMed PMID: 24111502.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Randomized controlled trial of fish oil supplementation in pregnancy on childhood allergies. AU - Palmer,D J, AU - Sullivan,T, AU - Gold,M S, AU - Prescott,S L, AU - Heddle,R, AU - Gibson,R A, AU - Makrides,M, Y1 - 2013/09/21/ PY - 2013/07/01/accepted PY - 2013/10/12/entrez PY - 2013/10/12/pubmed PY - 2014/7/11/medline KW - allergy prevention KW - eczema KW - fatty acids KW - pregnancy KW - randomized controlled trial SP - 1370 EP - 6 JF - Allergy JO - Allergy VL - 68 IS - 11 N2 - BACKGROUND: Diets high in n-3 long chain polyunsaturated fatty acids (LCPUFA) may modulate the development of IgE-mediated allergic disease and have been proposed as a possible allergy prevention strategy. The aim of this study was to determine whether n-3 LCPUFA supplementation of pregnant women reduces IgE-mediated allergic disease in their children. METHODS: Follow-up of children (n = 706) at hereditary risk of allergic disease in the Docosahexaenoic Acid to Optimise Mother Infant Outcome randomized controlled trial. The intervention group (n = 368) was randomly allocated to receive fish oil capsules (providing 900 mg of n-3 LCPUFA daily) from 21 weeks' gestation until birth; the control group (n = 338) received matched vegetable oil capsules without n-3 LCPUFA. The diagnosis of allergic disease was made during medical assessments at 1 and 3 years of age. RESULTS: No differences were seen in the overall percentage of children with IgE-mediated allergic disease in the first 3 years of life between the n-3 LCPUFA and control groups (64/368 (17.3%) vs 76/338 (22.6%); adjusted relative risk 0.78; 95% CI 0.58-1.06; P = 0.11). Eczema was the most common allergic disease; 13.8% of children in the n-3 LCPUFA group had eczema with sensitization compared with 19.0% in the control group (adjusted relative risk 0.75; 95% CI 0.53-1.05; P = 0.10). CONCLUSIONS: Overall, n-3 LCPUFA supplementation during pregnancy did not significantly reduce IgE-associated allergic disease in the first 3 years of life. Further studies should examine whether the nonsignificant reductions in IgE-associated allergies are of clinical and public health significance. SN - 1398-9995 UR - https://www.unboundmedicine.com/medline/citation/24111502/Randomized_controlled_trial_of_fish_oil_supplementation_in_pregnancy_on_childhood_allergies_ L2 - https://doi.org/10.1111/all.12233 DB - PRIME DP - Unbound Medicine ER -